Media Statements

Emergent BioSolutions Sponsors Manufacturing Day 2022, Declaring Manufacturing Matters & Inspiring New Generation of Talent

NAM and MI Celebrate #MFGDay2022 to Give Students Inside Look at Modern Manufacturing, Emergent Leaders Tour Lansing, Michigan Manufacturing Site with Local High School Students Washington, D.C. –...

Emergent BioSolutions Statement on the Status of its Camden Manufacturing Facility 

GAITHERSBURG, Md., August 12, 2022 – Emergent (NYSE: EBS) received a communication from the FDA on August 10, 2022.  That communication included the issuance of a warning letter.  We share the...

Emergent’s Response to U.S. Senator Tammy Baldwin and Congressional Leaders Regarding Access to Naloxone

In response to a letter led by Senator Tammy Baldwin requesting manufacturers submit an FDA application to make naloxone available over-the-counter (OTC), Emergent expressed its commitment to...

Emergent Response to New Congressional Report

There is nothing new. This report details the same information we have transparently given to regulators and the media over the past two years. Emergent has been open and forthcoming with the FDA,...

Emergent BioSolutions Statement on the Federal Court of Appeals’ Ruling on NARCAN® Nasal Spray Patents

GAITHERSBURG, Md., February 10, 2022 – Today, the Court of Appeals for the Federal Circuit (CAFC) issued a decision affirming the District Court’s decision in our patent litigation case with...

Emergent BioSolutions Statement on Generic Version of NARCAN® Nasal Spray

Based on publicly available information, it appears that Teva Pharmaceutical Industries Ltd. has launched a generic naloxone nasal spray, prior to resolution of the related pending patent...

Emergent Releases Inaugural ESG Report

GAITHERSBURG, M.D. – Emergent BioSolutions (NYSE: EBS) today released the inaugural edition of its environmental, social and governance (ESG) report. The report documents Emergent’s approach to...

Emergent and HHS Agree to End CIADM Arrangement

Emergent BioSolutions (NYSE: EBS) and the U.S. Department of Health and Human Services (HHS) have mutually agreed to Emergent’s proposal to end its involvement in the Centers for Innovation in...

Emergent BioSolutions Sponsoring MFG Day 2021, Inspiring New Generation of Manufacturing Talent

Advancing Mission of Nationwide “Creators Wanted” Workforce Campaign, MFG Day Highlights Modern Manufacturing Careers for Students, Parents, Teachers and Leaders Washington, D.C. – The...

Emergent BioSolutions Takes a Stand Against the Opioid Epidemic on International Overdose Awareness Day

Today, Emergent BioSolutions recognizes International Overdose Awareness Day, as part of Overdose Awareness Week, and the dedicated efforts of lifestyle influencer Dani Schaffer to address the...

Emergent BioSolutions Statement on Status of its Response to FDA Observations Related to the Company’s Baltimore Bayview Facility

GAITHERSBURG, Md., May 12, 2021 – At Emergent (NYSE: EBS), we have responded to FDA’s observations with a comprehensive quality enhancement plan. We have already started making improvements and...

Emergent CEO Remarks from Q1’21 Earnings

Thank you, Bob, and good afternoon to everyone. Thank you for joining us. As you know, we have been in the news lately primarily related to our COVID-19 manufacturing activities. As a result and...

This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.